Literature DB >> 23732855

The "stop" and "go" of nicotine dependence: role of GABA and glutamate.

Manoranjan S D'Souza1, Athina Markou.   

Abstract

Nicotine plays an important role in the initiation and maintenance of tobacco smoking. Importantly, chronic nicotine exposure alters the function of brain reward systems, resulting in the development of a nicotine-dependent state. This nicotine-dependent state is associated with aversive affective and somatic signs upon abstinence from smoking, often leading to relapse in abstinent smokers. This article reviews the role of the major excitatory and inhibitory neurotransmitters glutamate and γ-aminobutyric acid (GABA), respectively, in both the reinforcing effects of nicotine and development of nicotine dependence. Evidence suggests that blockade of glutamatergic neurotransmission attenuates both nicotine intake and nicotine seeking. In contrast, both nicotine intake and nicotine seeking are attenuated when GABA neurotransmission is facilitated. In conclusion, medications that either attenuate/negatively modulate glutamatergic neurotransmission or facilitate/positively modulate GABA neurotransmission may be useful for promoting smoking cessation in humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23732855      PMCID: PMC3662348          DOI: 10.1101/cshperspect.a012146

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  103 in total

Review 1.  Cellular and synaptic mechanisms of nicotine addiction.

Authors:  Huibert D Mansvelder; Daniel S McGehee
Journal:  J Neurobiol       Date:  2002-12

Review 2.  The reinstatement model of drug relapse: history, methodology and major findings.

Authors:  Yavin Shaham; Uri Shalev; Lin Lu; Harriet de Wit; Jane Stewart
Journal:  Psychopharmacology (Berl)       Date:  2002-10-26       Impact factor: 4.530

3.  Current cigarette smoking prevalence among working adults--United States, 2004-2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-09-30       Impact factor: 17.586

4.  The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice.

Authors:  Neil E Paterson; Svetlana Semenova; Fabrizio Gasparini; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

Review 5.  Desensitization of neuronal nicotinic receptors.

Authors:  Michael W Quick; Robin A J Lester
Journal:  J Neurobiol       Date:  2002-12

6.  Selective blockade of drug-induced place preference conditioning by ACPC, a functional NDMA-receptor antagonist.

Authors:  Marius Papp; Piotr Gruca; Paul Willner
Journal:  Neuropsychopharmacology       Date:  2002-11       Impact factor: 7.853

7.  Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) microinfusions into the nucleus accumbens shell or ventral tegmental area attenuate the reinforcing effects of nicotine in rats.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-08-31       Impact factor: 5.250

8.  Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat.

Authors:  Paola Fadda; Maria Scherma; Alessandra Fresu; Maria Collu; Walter Fratta
Journal:  Synapse       Date:  2003-10       Impact factor: 2.562

9.  The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse.

Authors:  Andrew J McGeehan; M Foster Olive
Journal:  Synapse       Date:  2003-03       Impact factor: 2.562

Review 10.  The ups and downs of addiction: role of metabotropic glutamate receptors.

Authors:  Paul J Kenny; Athina Markou
Journal:  Trends Pharmacol Sci       Date:  2004-05       Impact factor: 14.819

View more
  21 in total

Review 1.  Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy.

Authors:  Samuel A Barnes; Douglas J Sheffler; Svetlana Semenova; Nicholas D P Cosford; Anton Bespalov
Journal:  Biol Psychiatry       Date:  2018-03-09       Impact factor: 13.382

2.  GABA receptors differentially regulate life span and health span in C. elegans through distinct downstream mechanisms.

Authors:  Fengling Yuan; Jiejun Zhou; Lingxiu Xu; Wenxin Jia; Lei Chun; X Z Shawn Xu; Jianfeng Liu
Journal:  Am J Physiol Cell Physiol       Date:  2019-08-21       Impact factor: 4.249

Review 3.  Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?

Authors:  Timothy E Albertson; James Chenoweth; Jonathan Ford; Kelly Owen; Mark E Sutter
Journal:  J Med Toxicol       Date:  2014-12

4.  Regional GABA Concentrations Modulate Inter-network Resting-state Functional Connectivity.

Authors:  Xi Chen; Xiaoying Fan; Yuzheng Hu; Chun Zuo; Susan Whitfield-Gabrieli; Daphne Holt; Qiyong Gong; Yihong Yang; Diego A Pizzagalli; Fei Du; Dost Ongur
Journal:  Cereb Cortex       Date:  2019-04-01       Impact factor: 5.357

Review 5.  Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives.

Authors:  Maria Scherma; Anna Lisa Muntoni; Miriam Melis; Liana Fattore; Paola Fadda; Walter Fratta; Marco Pistis
Journal:  Psychopharmacology (Berl)       Date:  2016-01-04       Impact factor: 4.530

6.  Activation of PPARγ Attenuates the Expression of Physical and Affective Nicotine Withdrawal Symptoms through Mechanisms Involving Amygdala and Hippocampus Neurotransmission.

Authors:  Esi Domi; Francesca Felicia Caputi; Patrizia Romualdi; Ana Domi; Giulia Scuppa; Sanzio Candeletti; Alison Atkins; Markus Heilig; Gregory Demopulos; George Gaitanaris; Roberto Ciccocioppo; Massimo Ubaldi
Journal:  J Neurosci       Date:  2019-11-04       Impact factor: 6.167

7.  Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys.

Authors:  Sarah L Withey; Michelle R Doyle; Jack Bergman; Rajeev I Desai
Journal:  J Pharmacol Exp Ther       Date:  2018-05-21       Impact factor: 4.030

Review 8.  Glial cells as therapeutic targets for smoking cessation.

Authors:  Mohit Kumar; Adewale Adeluyi; Erin L Anderson; Jill R Turner
Journal:  Neuropharmacology       Date:  2020-05-24       Impact factor: 5.250

9.  Lack of correlation between CSF glutamate levels and PSQI scores in heavy smokers.

Authors:  Jinzhong Xu; Hui Li; Fan Wang; Zeping Xu; Guohua Li; Cheng Ding; Junnan Wu; Yimin Kang; Hong Li; Heng Xu; Yanlong Liu
Journal:  Sleep Breath       Date:  2018-08-07       Impact factor: 2.816

10.  Neurobiological Considerations for Tobacco Use Disorder.

Authors:  Megha Chawla; Kathleen A Garrison
Journal:  Curr Behav Neurosci Rep       Date:  2018-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.